stockrow
Friday 6 November 2026
Export ADAPY’s income statement to Excel — free account
Adaptimmune Therapeutics PLC
ADAPY Healthcare Biotechnology
Adaptimmune Therapeutics PLC’s revenue for fiscal 2025 (year ended December 2025) was $5.9 million, down 96.7% from fiscal 2024.
- Revenue
- −89.3%
- EPS
- −140.7%
- Free cash flow
- −174.7%
Quarter to June 2025, against a year earlier
0.02
0.00
0.00%
Follow ADAPY
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 3 | 2 | 5 | 5 | 1 | 3 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(23.33) | (6.11) | (5.52) | (4.16) | (1.11) | 2.36 | (4.17) | 9.77 | 3.21 | 1.40 |
P/S ratio |
0.12 | 0.77 | 2.50 | 9.92 | 95.02 | 194.01 | 48.43 | 9.41 | 16.50 | 20.54 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 299.93 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(51.29) | (14.10) | (11.83) | (8.21) | (1.74) | 2.26 | (8.00) | 7.83 | 1.75 | 2.65 |
P/Operating CF |
(0.23) | (3.98) | (10.28) | 131.84 | 4.36 | (26.28) | (10.05) | (17.67) | (29.24) | 123.05 |
Beneish M-Score |
16.71 | 1.76 | (1.62) | 1.53 | (1.49) | (1.90) | 5,239.88 | (2.02) | (2.20) | — |
P/B ratio |
0.00 | 10.45 | 3.82 | 3.29 | 2.84 | 2.25 | 1.02 | 2.27 | 3.08 | 1.76 |
Price to Tangible BV |
0.00 | 30.18 | 3.85 | 3.31 | 2.85 | 2.26 | 1.04 | 2.28 | 3.10 | 1.77 |
EV/Sales |
0.12 | 0.20 | 0.40 | 3.13 | 38.68 | 106.27 | 22.83 | 5.96 | 11.00 | 7.76 |
EV/EBITDA |
0.00 | 4.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(0.04) | (0.48) | (0.17) | (0.60) | 22.17 | (7.85) | (0.53) | (3.40) | (7.66) | (2.29) |
EV/FCF |
(0.04) | (0.46) | (0.17) | (0.50) | 122.09 | (7.44) | (0.51) | (3.25) | (5.28) | (1.81) |
Quick Ratio |
1.64 | 2.56 | 2.03 | 3.29 | 5.92 | 9.43 | 3.21 | 8.40 | 2.81 | 4.54 |
Current Ratio |
2.04 | 2.88 | 2.85 | 3.96 | 6.64 | 10.19 | 3.51 | 9.46 | 3.10 | 4.94 |
Net Debt/EBITDA |
0.47 | 0.61 | 1.13 | 1.17 | 2.23 | 2.76 | 0.51 | 2.75 | 2.77 | 2.61 |
Debt/Assets |
0.00% | 20.39% | 0.00% | 6.19% | 4.93% | 4.64% | 12.65% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 4.24 | 0.00 | 0.25 | 0.11 | 0.06 | 0.19 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.04 | 0.67 | 0.20 | 0.07 | 0.01 | 0.01 | 0.00 | 0.21 | 0.15 | 0.05 |
Operating CF/Net income |
(4.84) | 1.02 | 1.24 | 0.86 | (0.07) | 0.41 | 0.82 | 1.09 | 0.77 | 0.67 |
Capex/Depreciation |
0.00 | (0.12) | (0.50) | (4.90) | (1.34) | (0.38) | (0.38) | (0.60) | (4.51) | (3.89) |
Interest Coverage |
(9.99) | (27.84) | — | (106.40) | (148.18) | (57.23) | (50.21) | (28.96) | (36.17) | (65.58) |
| 112.01% | (273.57%) | (187.61%) | (114.96%) | (57.78%) | (55.97%) | (74.04%) | (42.46%) | (38.00%) | (33.58%) | |
| 16.27% | (27.17%) | (37.24%) | (41.44%) | (34.34%) | (41.12%) | (59.86%) | (34.24%) | (27.20%) | (26.71%) | |
ROIC |
(753.70%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (153.09%) | (123.30%) | 0.00% | 0.00% |
Return on Tangible Assets |
81.64% | (46.83%) | (61.32%) | (67.70%) | (41.23%) | (33.63%) | (117.02%) | (39.34%) | (35.68%) | (38.40%) |
Average Days of Receivables |
645.16 | 29.49 | 4.97 | 99.96 | 44.64 | 12.82 | 6,724.52 | 1.18 | 1.99 | 38.05 |
Research and Development Expense of Revenue |
810.18% | 62.70% | 209.87% | 470.48% | 1,806.64% | 2,313.49% | 8,689.93% | 165.14% | 230.98% | 449.28% |
Selling, General and Administrative Expense of Revenue |
601.22% | 37.46% | 121.95% | 233.49% | 931.94% | 1,157.02% | 3,867.29% | 73.27% | 82.22% | 163.46% |
Intangible Assets out of Total Assets |
0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 |
Share Based Compensation of Revenue |
(19.53%) | 6.14% | 19.53% | 67.19% | 335.49% | 263.11% | 985.12% | 27.23% | 28.56% | 62.13% |
Graham Net Nets |
(15.59) | (0.34) | (0.24) | 0.03 | 0.26 | 0.38 | 0.50 | 0.36 | 0.24 | 0.45 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(2,166.67%) | (50.00%) | (73.83%) | (61.08%) | (26.67%) | (17.63%) | (109.17%) | (17.91%) | (11.82%) | (24.03%) |
Free Cash Flow Yield |
(2,432.09%) | (55.13%) | (96.65%) | (63.73%) | 0.33% | (7.36%) | (91.76%) | (19.48%) | (12.62%) | (20.90%) |
Revenue per Share |
0.02 | 0.71 | 0.30 | 0.17 | 0.04 | 0.03 | 0.01 | 0.61 | 0.43 | 0.20 |
Operating CF per Share |
(0.46) | (0.29) | (0.70) | (0.88) | 0.07 | (0.38) | (1.07) | (1.07) | (0.62) | (0.68) |
Capex per Share |
0.00 | (0.01) | (0.02) | (0.18) | (0.06) | (0.02) | (0.03) | (0.05) | (0.28) | (0.18) |
Free Cash Flow per Share |
(0.46) | (0.30) | (0.72) | (1.06) | 0.01 | (0.40) | (1.10) | (1.12) | (0.90) | (0.86) |
Cash per Share |
0.10 | 0.60 | 0.73 | 1.27 | 2.37 | 2.58 | 0.85 | 2.11 | 2.37 | 2.56 |
Shareholders Equity per Share |
0.12 | 0.05 | 0.20 | 0.51 | 1.32 | 2.40 | 1.18 | 2.54 | 2.31 | 2.35 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.12 | 0.05 | 0.20 | 0.51 | 1.32 | 2.40 | 1.18 | 2.54 | 2.31 | 2.35 |
Free Cash Flow |
(121.96) | (75.11) | (145.76) | (171.51) | 1.95 | (56.50) | (115.58) | (109.10) | (78.78) | (60.95) |
Working Capital |
23.08 | 122.19 | 134.76 | 190.87 | 352.92 | 359.08 | 86.15 | 206.66 | 155.87 | 158.48 |
Capital Expenditures |
(0.05) | (1.90) | (4.88) | (29.74) | (8.78) | (2.91) | (3.07) | (4.71) | (24.46) | (12.78) |
Net Current Asset Value |
13.92 | (46.34) | (35.55) | 8.33 | 151.87 | 288.24 | 62.58 | 201.24 | 152.02 | 130.38 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.01 | 0.08 | 1.10 | 1.43 | 0.73 | 2.74 | 0.08 | 0.65 | 0.90 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
2.20 | 0.51 | 0.19 | 0.11 | 0.22 | 0.27 | 0.26 | 0.22 | 0.13 | 0.12 |
Cash ROIC |
(210.56%) | (35.15%) | (78.18%) | (55.90%) | 0.33% | (7.74%) | (48.94%) | (24.14%) | (19.16%) | (17.53%) |
Accounts Receivable Turnover |
0.48 | 23.42 | 14.60 | 6.63 | 13.80 | 0.38 | 0.11 | 299.02 | 44.88 | 2.34 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | — | — | — | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | — | — | — | — | — | — | — | — |
Average Receivables |
12.43 | 7.60 | 4.13 | 4.09 | 0.45 | 10.41 | 10.43 | 0.20 | 0.84 | 6.08 |
Average Payables |
28.80 | 24.56 | 6.44 | 6.43 | 7.25 | 6.37 | 5.22 | 6.23 | 9.86 | 19.07 |
Average Assets |
154.89 | 264.52 | 305.77 | 399.23 | 460.34 | 316.34 | 229.14 | 278.94 | 257.83 | 267.94 |
Average Common Equity |
22.50 | 26.27 | 60.70 | 143.92 | 273.59 | 232.43 | 185.26 | 224.93 | 184.56 | 213.17 |
Columns are period end dates · fundamentals updated 26 Oct 2026